Inspyr Therapeutics, Inc. Share Price Other OTC
Equities
NSPX
US45782A4031
Biotechnology & Medical Research
Sales 2021 | - | Sales 2022 | - | Capitalization | 241K 18.85M |
---|---|---|---|---|---|
Net income 2021 | 2M 156M | Net income 2022 | -1M -78.21M | EV / Sales 2021 | - |
Net cash position 2021 | 197K 15.41M | Net Debt 2022 | 305K 23.85M | EV / Sales 2022 | - |
P/E ratio 2021 |
-0.4
x | P/E ratio 2022 |
-0.23
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 100% |
Managers | Title | Age | Since |
---|---|---|---|
Silvestre Raul
CEO | Chief Executive Officer | 53 | - |
Michael Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 10/10/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Scott Ogilvie
BRD | Director/Board Member | 69 | 31/01/08 |
Silvestre Raul
CEO | Chief Executive Officer | 53 | - |
Claire Thomas
BRD | Director/Board Member | 68 | 11/10/16 |
1st Jan change | Capi. | |
---|---|---|
+14.64% | 118B | |
+13.00% | 106B | |
-3.79% | 24.28B | |
+1.14% | 21.96B | |
-9.35% | 18.16B | |
-42.28% | 16.37B | |
-18.60% | 15.56B | |
+5.24% | 13.63B | |
+28.31% | 12.27B |